Our Stories
Patient & Caregiver Stories
Nick shares his experience recognizing early signs of stomach cancer, navigating diagnosis, learning the importance of HER2 testing, and finding strength through treatment, family support, and hope for the future.
Armando’s journey with cholangiocarcinoma (CCA), a rare biliary tract cancer, reflects the power of connection and resilience. Throughout his experience, he shared how the support of loved ones brought him strength and peace. His words continue to inspire the cancer community, honoring the courage and spirit he carried into every conversation.
Lisa shares the story of her son Jace, who faced his diagnosis of a rare brain cancer with courage and compassion. His outlook continues to inspire the support Lisa now offers to other families navigating childhood cancer.
Science Stories
Discover how advancing HER2 science is reshaping cancer care. By deepening understanding of tumor complexity and leveraging biomarker-driven approaches, we are enabling more precise therapies and driving innovation to improve outcomes for patients with HER2-expressing cancers and other areas of high unmet need.
Extensive-stage small cell lung cancer remains one of the most aggressive and difficult-to-treat cancers, with most patients relapsing within months of initial therapy. Maintenance therapy may turn the period of stability after their first treatment into an opportunity to extend response and delay relapse.
We strive to put patient priorities first in our research, advancing our understanding of sleep conditions and the needs of those with narcolepsy and idiopathic hypersomnia.
Leader Perspectives
We’ve placed a strategic focus on HER2 development to help address the ongoing unmet needs faced by patients and their families. Learn how the landscape of HER2-targeted agents in cancer care is evolving and how we’re continuing to build our HER2 platform to drive long-term impact for patients and their families
The pace of progress in oncology continues to accelerate, driven by a deeper understanding of tumor biology and increasingly precise therapeutic approaches. That momentum is particularly meaningful in rare cancers, where unmet need remains high and rigorous science has the potential to make a real difference for patients.
Corporate Sustainability and Social Impact, or CSSI, helps us embed the needs of patients, our people, communities, and the planet into how we operate and make decisions. It is a business discipline that supports trust, resilience, and long-term value.